Furthermore, LILRB4 expression on monocytic MDSCs plays a crucial role in mediating cancer-related immunosuppression, and its blockade can reverse this suppression, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs) 164. This evidence concerns the gene LILRB4 and cancer.